On March 5, 2019 the FDA approved a new nasal spray medication- Spravato (esketamine) for treatment-resistant depression, available only at a certified doctor’s office or clinic.
Ketamine represents a major step forward in the treatment of depression and
suicide prevention. ADAA recognizes that clinicians want to offer their patients evidence-based options which have passed through the numerous stages of FDA testing, and this marks the first FDA approval of a ketamine product for a psychiatric indication. This is also the first antidepressant with a novel mechanism of action that we have had in decades. Read more: bit.ly/2VTD5I2
Written by
ADAATeamLise
Partner
To view profiles and participate in discussions please or .
It is very good that we have now new medication for depression and anxiety, because it allow us to return as soon as possible to our life. In depression time we cannot work and if we cannot work, we don't have money for treatments, so more depression and anxiety will come. With this new medication we can function earlier as a normal person and we can work for money.
in reply to
I am alone. Nobody will take care of me if I am ill, I have no money if I cannot work. What can I do?
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Treatment resistant depression 
ADAA Story of Triumph: Ruth's Story
